Incyte up after European Commission expands use of cancer drug

Incyte

17/12/2025 16:40

** Shares of drugmaker Incyte INCY.O rise 1.9% to $98.83

** Incyte says that the European Commission has approved its cancer drug Minjuvi in combination with lenalidomide and rituximab

** The new approval expands the use for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy

** FL is a type of cancer that begins in the lymph system, a part of the immune system

** Minjuvi was already approved by the EC in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma

** Including session moves, stock up 42.2% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))